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Tomonori Igarashi, MD, PHD,* Maria Strom, PHD,* David S. Rosenbaum, MD,*
J. Kevin Donahue, MD*
Cleveland, Ohio; and Tokyo, Japan
Objectives The aim of this study was to evaluate the links between connexin43 (Cx43) expression, myocardial conduction
velocity, and ventricular tachycardia in a model of healed myocardial infarction.
Background Post-infarction ventricular arrhythmias frequently cause sudden death. Impaired myocardial conduction has pre-
viously been linked to ventricular arrhythmias. Altered connexin expression is a potential source of conduction
slowing identified in healed scar border tissues. The functional effect of increasing border-zone Cx43 has not
been previously evaluated.
Methods Twenty-five Yorkshire pigs underwent anterior infarction by transient left anterior descending coronary artery oc-
clusion, followed by weekly testing for arrhythmia inducibility. Twenty animals with reproducibly inducible sus-
tained monomorphic ventricular tachycardia were randomized 2:1:1 to receive AdCx43, Adgal, or no gene
transfer. One week later, animals underwent follow-up electrophysiologic study and tissue assessment for sev-
eral functional and molecular measures.
Results Animals receiving AdCx43 had less electrogram fractionation and faster conduction velocity in the anterior-
septal border zone. Only 40% of AdCx43 animals remained inducible for ventricular tachycardia, while
100% of controls were inducible after gene transfer. AdCx43 animals had 2-fold higher Cx43 protein levels
in the anterior-septal infarct border, with similar percents of phosphorylated and intercalated disk-localized
Cx43 compared with controls.
Conclusions These data mechanistically link Cx43 expression to slow conduction and arrhythmia susceptibility in the healed scar
border zone. Targeted manipulation of Cx43 levels improved conduction velocity and reduced ventricular tachycardia
susceptibility. Cx43 gene transfer represents a novel treatment strategy for post-infarction arrhythmias. (J Am Coll
Cardiol 2012;60:1103–10) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.042Sudden cardiac arrest remains the leading cause of death in
developed countries. Previous research has shown that the
majority of cases of sudden cardiac arrest occur in the setting
of acute or chronic ischemic heart disease (1). Ventricular
tachycardia (VT) is a common cause of sudden cardiac arrest
in patients with healed myocardial infarction (MI) scars,
and electrophysiologic study (EPS) generally localizes the
VT circuit to the MI scar border (2). The underlying
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accepted April 24, 2012.arrhythmia mechanism for scar-related VT is re-entry
through this border zone. Wavelength theory suggests that
re-entry should be extinguished by increasing either con-
duction velocity (CV) or tissue refractory properties. We
previously eliminated arrhythmia inducibility by delaying
repolarization (3). Here, we focus on the conduction side of
the equation.
See page 1111
Factors previously shown to impede conduction through
healed scar include reduced intercellular coupling and dis-
continuities in tissue architecture (2,4). The major factors
controlling intercellular coupling are gap junction density
and function. Connexin43 (Cx43) is the predominate ven-
tricular gap junction protein (5). Previous studies have
shown reduced border-zone Cx43 expression and gap junc-
tion localization, persisting chronically after MI (4,6). In the
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these Cx43 changes paired with
reductions in cellular excitability
have been linked to CV slowing
and VT (7,8), but longitudinal
study has shown that the deter-
minants of cellular excitability
(resting membrane potential, ac-
tion potential amplitude, and up-
stroke velocity) returned to nor-
mal within 2 weeks of infarction
(9). Although these investigators
and others have implicated gap
junction remodeling in the
pathogenesis of VT coming from
the healed infarct border, it has thus far been challenging to
directly evaluate the association between reduced Cx43 and
VT in chronic scar. Here, we address this issue using our
previously validated ventricular gene transfer methods and
porcine model of healed MI and inducible VT.
Methods
For full details of methods, please see the Online Appendix.
Briefly, 25 Yorkshire pigs (weight 25 to 30 kg) were studied
as follows. At the start of the study, animals underwent
infarction and defibrillator implantation. Weekly thereafter,
animals underwent noninvasive EPS through their defibril-
lators. Four weeks after MI, animals with repeatedly induc-
ible sustained monomorphic VT (SMVT) at both 3-week
and 4-week post-MI EPS were randomized 2:1:1 to gene
transfer with AdCx43, Adgal, or no virus. Immediately
before and 1 week after gene transfer, animals underwent
invasive EPS. After the follow-up EPS, animals were
sacrificed, and their hearts were harvested for optical map-
ping, histology, and Cx43 analyses. The Adgal virus
controls and the no-virus controls were compared as a single
group with the AdCx43 animals by prospective design.
Continuous variables were analyzed using Student t tests or
2-way analysis of variance as appropriate. VT inducibility
was assessed using chi-square tests. All statistical tests were
conducted at the 0.05 significance level. Data are presented
as mean SD (or as medians and ranges because of the lack
of a normal distribution and the very small numbers for the
post hoc substudy within the AdCx43 group).
Results
Twenty-five pigs started the study. Five were excluded
before gene transfer: 2 died during infarction, 1 died
suddenly during the first day after infarction, 1 developed a
refractory defibrillator infection, and 1 had no inducible
SMVT. We could induce ventricular fibrillation (VF) in 10%
to 25% of animals each week with programmed stimulation
(including the pre-MI and post–gene transfer EPS). Unlike
the reproducibility that we saw in SMVT induction, VF was
Abbreviations
and Acronyms
CV  conduction velocity
Cx43  connexin43
EPS  electrophysiologic
study
MI  myocardial infarction
SMVT  sustained
monomorphic ventricular
tachycardia
VF  ventricular fibrillation
VT  ventricular
tachycardiaonly a sporadic finding and was not consistently induced everyweek in any animal. Overall, the pre–gene transfer observa-
tions in this study (MI survival, VF and SMVT inducibility)
were similar to our previously published experience with the
porcine healed MI–VT model (3,10).
Twenty animals met our prospective enrollment criteria
of reproducibly inducible SMVT at both the 3-week and
4-week post-MI EPS. These animals received coronary
artery and venous infusion of AdCx43 (10 animals), Adgal
(5 animals), or no virus (5 animals) immediately after the
4-week post-MI EPS. Repeat electrophysiologic testing 1
week after gene transfer revealed that only 4 of the 10
AdCx43 animals continued to have any inducible VT, while
all 10 controls remained inducible (p  0.01) (Fig. 1).
Functional impact of increasing Cx43 in healed scar
border. We used 2 methods to determine the functional
effects of Cx43 gene transfer: paced fractionated electrogram
duration, an in vivo measure of electrogram fractionation
correlated with local conduction properties (11), and ex vivo
optical mapping that has been shown to reliably measure
tissue CV (12). Because of limitations in equipment avail-
ability for these methods, we could perform paced fraction-
ated electrogram duration only in the first 10 animals and
optical mapping in the second 10 animals of the study
(5 Cx43 animals and 5 controls per measure). Both CV
measures showed conduction improvement with Cx43 over-
expression (Fig. 2). Paced fractionated electrogram duration
shortened from the pre–gene transfer to the post–gene
transfer EPS in AdCx43 animals but not controls (13 
5 ms vs. 5  4 ms, p  0.04). Likewise, optical mapping
howed significantly faster CV in anteroseptal tissues from
dCx43 animals compared to controls (50  10 cm/s vs.
1  12 cm/s, p  0.02).
Figure 1 Arrhythmia Inducibility
The bar graph shows the percent of animals with sustained monomorphic ven-
tricular tachycardia (VT) or ventricular fibrillation (VF) induced at the pre–
myocardial infarction (MI), pre–gene transfer (GTx), and 1-week post-GTx time
points. The percent of animals with sustained monomorphic VT was signifi-
cantly reduced in the AdCx43 group relative to controls. There were no statisti-
cally significant differences in VF inducibility. *p  0.01.
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fibrosis, we tested for this potential confounder to our CV
results by quantifying fibrosis in Masson’s trichrome–
stained microsections from the optically mapped tissue
wedges where we had measured CV. As expected in this
scarred region, fibrosis was extensive and considerably vari-
able between animals, but we found no significant differ-
ences in percent fibrosis between groups (23  8% in
dCx43 animals vs. 14  4% in controls, p  0.35). These
ata further connect our measured CV improvement to
ncreased Cx43 expression rather than between-group dif-
erences in other factors.
x43 expression and location. We assessed anterior-septal
order-zone Cx43 expression using Western blot analysis
Figs. 3A and 3B). The Cx43 antibody recognized total
x43, so we distinguished the differentially phosphorylated
ariants by their molecular weights. AdCx43 animals had
-fold higher levels of total Cx43 compared with controls
3.4 0.4 vs. 1.7 0.4, p 0.01), with similar distribution
across the individual phosphorylated bands (AdCx43 ani-
mals: nonphosphorylated 21  3%, P1 40  1%, and P2
39  2%; controls: nonphosphorylated 20  3%, P1 37 
2%, and P2 43  3%). We evaluated connexin localization
Figure 2 Functional Effects of Connexin43 GTx
(A) The left panel shows the change in paced fractionated electrogram duration (P
panel shows electrogram examples. (B) Transmural conduction velocity (CV) was f
maps are shown in the right panel. The wedges were paced from the endocardial
area is the last activated along the transmural face of the tissue wedge (n  5 peusing confocal immunohistochemistry (Figs. 3C and 3D).Cx43 was highly lateralized in the border-zone tissues of all
animals, but we saw a similar percent of the total expressed
Cx43 localized to the intercalated disk in both groups (26
6% of total Cx43 in AdCx43 animals vs. 25  4% in
controls). Overall, these data suggest similar processing of
transgenic and endogenous Cx43 with similar relative per-
cents of phosphorylated and intercalated disk-localized
Cx43 in all animals but an absolute increase in phosphory-
lated or intercalated disk-localized Cx43 in the AdCx43
animals due to the bulk effect of increased total Cx43
expression.
Electrocardiography, echocardiography, and clinical ob-
servations. On a daily basis, we assessed activity level,
appetite, respiration, and hydration. We also weighed the
animals before infarction, gene transfer, and sacrifice.
Throughout the study, AdCx43 and control animals did not
differ for any of these measures. We compared electrocar-
diographic and echocardiographic measurements and found
no significant differences either between groups or within
groups comparing before and after gene transfer (Table 1).
Limitations to efficacy. In an attempt to better understand
factors affecting efficacy, we performed post hoc analyses
within the AdCx43 group, comparing the 6 AdCx43
omparing pre–gene transfer (GTx) to post-GTx electrophysiologic study. The right
in the AdCx43 group than in controls (left panel). Example transmural isochronal
. The blue coloration marks the region of earliest activation, and the red-colored
p). †p  0.05.FED) c
aster
border
r grouanimals rendered uninducible with the 4 AdCx43 animals
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uninducible animals had increased total connexin, interca-
lated disk localized connexin, and CV relative to those that
remained inducible, although there was considerable overlap
in the data range between the 2 groups (Table 2). In our
limited investigation of fibrosis (evaluated only in the tissue
wedges in which we measured CV), uninducible animals
also had higher fibrosis content.
We evaluated VT characteristics in the AdCx43 animals.
Twelve-lead configurations of the induced VTs before gene
Figure 3 Cx43 Expression in the Anterior-Septal Border Zone
(A) Representative immunoblots of connexin43 (Cx43) and beta-actin from control
phorylated Cx43 (NP) are depicted. (B) The bar graph shows quantification of ban
Cx43, and the relative distribution of Cx43 in the NP, P1, and P2 bands is demarc
from anterior-septal border-zone samples. (D) Percent of Cx43 co-localized with pa
Electrocardiographic and Echocardiographic DataTable 1 Electrocardiographic and Echocardiographic Data
Variable
Controls
Pre-MI Pre-GTx
Electrocardiography
P-wave duration (ms) 64 1 75 2
PR interval (ms) 107 4 115 4
QRS duration (ms) 62 4 84 4
QTc interval (ms) 410 14 422 14
RR interval (ms) 560 30 422 14
Echocardiography
LVEF 69 2
LV internal diameter-diastole 3.8 0.1
Septal width in diastole 0.9 0.1
LV posterior width in diastole 0.9 0.1
Values are mean SD. The pre-MI study was performed immediately before the infarct procedure,
was performed 1 week after GTx (post-MI week 5). Echocardiography was not performed at the pr
comparing between the control and AdCx43 groups.
GTx  gene transfer; LV  left ventricular; LVEF  left ventricular ejection fraction; MI  myocardial intransfer were not distinctly different between successes and
failures within the AdCx43 group. Before gene transfer,
animals rendered uninducible had an average of 1.3  0.8
distinct VTs per animal, and continually inducible animals
had 2.3  0.5 VTs per animal. In the post–gene transfer
study, 3 of the 4 treatment failures had only 1 inducible VT
per animal, but the remaining animal now had 5 inducible
configurations. One of the pre–gene transfer VT configu-
rations remained inducible in 3 of the 4 failures. The other
failure no longer had either of the 2 pre–gene transfer VT
d AdCx43 (Cx) animals. Phosphorylated Cx43 bands (P1 and P2) and nonphos-
sity for Cx43, normalized to beta-actin expression. Bar height indicates total
y the colored bands. (C) Immunofluorescent labeling of Cx43 and pan-cadherin
erin indicating intercalated disk localization (p  NS). *p  0.01.
AdCx43 Animals
Post-GTx Pre-MI Pre-GTx Post-GTx
74 3 70 3 80 3 78 5
115 4 118 2 121 4 124 6
78 3 67 2 74 3 77 2
411 11 454 12 429 10 431 7
529 30 628 25 522 29 544 36
39 4 66 2 38 2
4.9 0.2 3.4 0.1 4.5 0.1
0.6 0.1 0.8 0.1 0.8 0.1
0.9 0.1 0.8 0.1 0.9 0.1
GTx study was performed immediately the GTx procedure (post-MI week 4), and the post-GTx study
me point. There were no significant differences comparing pre-GTx with post-GTx within groups or(C) an
d inten
ated b
n-cadhthe pre-
e-GTx tifarction; QTc  Bazett’s corrected QT interval.
nternal
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The animal with 5 VT configurations had 4 new configu-
rations in addition to 1 of the 2 configurations seen before
gene transfer.
Discussion
Post-infarct patients have a risk for ventricular arrhythmias
that persists at a measurable level indefinitely. Post hoc analysis
of the Multicenter Automatic Defibrillator Implantation Trial
II showed that the highest mortality benefit and incidence of
appropriate defibrillator shocks occurred years after incident
MI (13). Limitations of currently available treatment options
for ventricular arrhythmias have motivated us and others to
search for novel strategies to solve this problem. A fundamental
step in this development process has been to define the
pathophysiological alterations underlying the target arrhythmia
that might be amenable to correction.
Mechanism of ventricular arrhythmias after MI. Surpris-
ingly little information is available about cellular and mo-
lecular mechanisms of ventricular arrhythmias after infarct
scar healing, which we define according to the time course
described by Holmes et al. (14) in large mammals as
completion of the necrotic (0 to 7 days after MI) and fibrotic
(7 to 21 or 28 days) phases and entry into the remodeling
phase that lasts indefinitely. Most of the data available on
post-infarct VT mechanisms come from dogs studied 4 to 5
days after infarction. At that early time point, the consid-
erable changes in border-zone myocyte electrophysiology
include decreased sodium and L-type calcium current den-
Comparison Within the AdCx43 Group BetweenN ninducible and Continued Inducible Animals ATable 2 Compariso Within the AdCx43 GroNoninducible and Continued Inducib
Me
Immunohistochemistry
Cx43 at intercalated disk (%)
Western blot
Total Cx43 (relative to beta-actin)
Cx43 in nonphosphorylated band (% of total) 2
Cx43 in P1 band (% of total) 3
Cx43 in Ps band (% of total) 3
Electrophysiologic study
VT configurations before gene transfer
PFED at sacrifice 5
Ex vivo optical mapping
Conduction velocity
Echocardiography
EF at sacrifice (%) 3
Change in EF from baseline (%) 2
LVID at sacrifice (cm)
Septal wall thickness at sacrifice (cm)
Histology
Fibrosis (% of total tissue area) 3
Because of the small numbers and post hoc nature, these data were
Cx43  connexin43; EF  ejection fraction; LVID  left ventricular i
duration; VT  ventricular tachycardia.sities with altered kinetics, decreased transient and delayedrepolarizing potassium currents, and both reduced and
lateralized Cx43 expression (7,8,15–20). The data from
dogs 4 to 5 days after MI are exceedingly important in
helping us understand, and eventually improve therapy for,
arrhythmias occurring in the days to weeks after infarction.
A problem with applying these findings to the healed scar is
that many of the ion channel alterations are resolved over
the succeeding weeks after infarction (9,21), so these obser-
vations are insufficient to explain VT arising weeks, months,
or years after MI.
What then is known about arrhythmias in the healed
scar? De Bakker et al. (2) mapped VT circuits in vivo during
cardiac surgical procedures for 72 patients with healed MIs.
They localized the vast majority of the VTs to focal areas in
the border zone 1.4 cm2 in diameter (countering a
common misconception that re-entrant VT circuits are
necessarily large, encircling the entire infarct scar). They
compared the tachycardia activation sequence with tissue
histology and found that VT consistently traveled through
areas where extensive fibrosis infiltrated between myocytes
(2,22,23). In separate work around the same time, Smith et
al. (4) found that the border-zone tissues had marked
alterations in the cellular distribution of connexins. Rather
than a normal localization at intercalated disks along the
ends of myocytes, they described a lateralization of connex-
ins across the entire cell membrane in border-zone myo-
cytes. Smith et al. did not map VT circuits, and they
described the connexin finding as a general property of
border-zone myocytes. These data led to what currently are
Gene Transferetw en
imals After Gene Transfer
oninducible Continued Inducible
Range Median Range
0.19 to 0.42 0.17 0.12 to 0.38
2.58 to 4.3 2.86 2.8 to 4.6
23.6 to 25.1 18 11.7 to 25.2
37.9 to 38.7 41 38.9 to 42.8
36.1 to 38.4 41 35.8 to 45.4
1 to 3 2 2 to 3
35 to 82 64 40 to 118
0.52 to 0.59 0.43 0.36 to 0.61
33 to 42 36 35 to 45
22 to27 29 26 to31
4.1 to 4.8 4.55 4.5 to 4.6
0.65 to 0.69 1.00 0.74 to 1.09
20 to 53 12 3 to 27
tistically analyzed and are presented as descriptive only.
dimension and end-diastole; PFED  paced fractionated electrogramfterup B
le An
N
dian
0.31
3.44
4
8
7
1
6
0.56
8
5
4.43
0.67
7
not stathe 2 prevailing hypotheses for post-infarct VT mechanism:
1108 Greener et al. JACC Vol. 60, No. 12, 2012
Cx43 Gene Therapy for Ventricular Tachycardia September 18, 2012:1103–10that the VT circuit is a “zigzag course” through surviving
myocytes in a maze of fibrosis, independent of cellular
electrophysiology, or that VT occurs as a function of
reduced connectivity and potentially altered myocyte excit-
ability or refractory properties.
We previously have reported validation data on the
porcine post-MI VT model demonstrating that the scar has
healed at post-MI week 4 and that the model shares many
common elements with VT seen chronically after infarction
in humans (10). The principal findings of our present study
are that Cx43 expression is decreased and intracellular
localization is lateralized. These alterations correlated with
heterogenous conduction by in vivo measures and slowed
CV during ex vivo testing. Gene transfer–mediated overex-
pression of Cx43 increased the absolute amount of phos-
phorylated and intercalated disk-localized Cx43, improved
CV, and reduced VT inducibility. These data solidly con-
nect Cx43 expression and function to ventricular CV and
arrhythmia mechanism. Our inability to completely elimi-
nate VT with this intervention suggests that other factors
(e.g., pattern or level of fibrosis, cellular excitability, and/or
repolarization) are involved as well.
Potential causes of treatment failure. An important con-
sideration for future attempts to refine the CV strategy for
VT elimination will be defining the causes of treatment
failure. As a first step in this process, we compared AdCx43
animals with successful elimination of VT with those that
remained inducible. Because we did not prospectively design
the comparison between successes and failures in the
AdCx43 group and we had very small numbers to work
with, we did not statistically analyze these data. Looking at
data trends between the 2 groups, we saw suggestions of
decreased Cx43 expression and intercalated disk localization,
increased Cx43 phosphorylation, decreased CV, decreased
fibrosis, and an increased number of baseline VTs per animal
in the treatment failures. Looking at VT configurations, we
saw that most of the treatment failures had continued induc-
ibility of at least 1 pre–gene transfer VT after therapy.
On the basis of these observations, possible explanations
for treatment failure include inadequate gene transfer,
altered Cx43 processing after gene transfer, incorrect tar-
geting of the gene transfer, increased mass or complexity of
the border-zone region in the failures, or the need to reach
a critical CV threshold to extinguish re-entry. Another
potential explanation given the complex anatomy created by
interdigitation of fibrosis, surviving normally functioning
myocytes, and potentially of surviving impaired myocytes is
that the outcome of the connexin gene transfer strategy
depends critically on having sufficient viable cardiomyocytes
capable of successful gene transfer, expression, and im-
proved function within the targeted slow conduction zone.
Differences in total Cx43 expression and CV support
inadequate gene transfer as a cause. Phosphorylation and
localization differences suggest the possibility of altered
protein processing. The persistence of pre–gene transfer VT
configurations suggests that the tissue target might havebeen missed. The larger number of baseline VTs per animal
and reduced fibrosis (i.e., greater myocyte mass within the
border zone) in the treatment failures suggests that improv-
ing CV might be insufficient to disrupt VT in areas with
more complex anatomic or functional defects. Because all of
the AdCx43 animals had improved CV relative to the
controls, the lower median CV in the treatment failures may
indicate the need to surpass a CV threshold to terminate
re-entry, although 1 animal had persistent VT inducibility
despite a CV of 63 cm/s, suggesting that a CV threshold
would not be a complete explanation for failure. Prospective
study with a much larger dataset is required to definitively
answer this question.
Study limitations. As in any research study, our data have
certain limitations that need to be considered when inter-
preting our results. Where possible, we validated our find-
ings with multiple measurements, but we could not com-
prehensively evaluate every bit of border zone to fully define
percent fibrosis or to eliminate the possibility of any
continued necrotic or inflammatory elements. We relied on
prior research for some of these conclusions. We also were
limited in both post-infarction and post–gene transfer study
durations because of practical issues of expense, pig size, and
the time course of gene expression with adenovirus vectors.
Longer term expression (e.g., with adeno-associated virus or
lentivirus vectors) would be needed for translational studies
or clinical use of this treatment strategy (24).
Another limitation of our study is whether the absence of
VT on EPS predicts long-term success. Certainly, EPS is
questionable as a screening tool to identify post-infarct
patients at risk for sudden death (25), but the available
research suggests an entirely different situation in patients
with known VT substrate. In radiofrequency ablation pa-
tients who started procedures with readily inducible VT and
who were then rendered completely uninducible by ablation,
80% to 95% remained free of VT on 2-year to 5-year
follow-up (26–28). These data suggest that the elimination
of VT inducibility is a valid end point in a population with
known, reproducible VT.
Safety issues. In limited safety analysis, we saw no sponta-
neous arrhythmias and no abnormalities of repolarization in
animals treated with AdCx43. We also saw no change in left
ventricular ejection fraction, no clinical signs of heart failure, or
other adverse events. One concern that comes from a strategy
of increased cellular connectivity is that we might cause
recovery of conduction in previously nonconducting areas and
create new zones of slow conduction. We did have 2 animals
(of 10) with new VT configurations after gene transfer, so we
cannot exclude this possibility. Better in vivo mapping methods
to more precisely define the areas of slow or absent conduction
before gene transfer with comparison with results after gene
transfer would be needed to fully evaluate this possibility.
Those methods are beyond our current capabilities.
Another theoretical concern is that forced increases in
cellular connectivity may allow the spread of toxins or death
signals during active ischemia. The published research on
1109JACC Vol. 60, No. 12, 2012 Greener et al.
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functioning connexins are essential for the protective effects
of ischemic preconditioning (29). Connexin function and
preconditioning have also been associated with a reduction
in ischemic arrhythmias (30). However, closure of connex-
ins during ischemia reduces infarct size in situations in
which preconditioning has not occurred (31). In 1 study,
infarct size decreased with transgenic expression of con-
nexin32, a connexin that does not close in response to
ischemia (32). Another study used gene transfer methods at
the time of ischemia, and thus gene expression a few days
after the ischemic insult, and found increased infarct size
(33). We did not assess recurrent ischemia after gene
transfer in this study, but our overexpression of wild-type
Cx43 and evidence of normal processing and function
suggest that the gene transfer-induced Cx43 proteins would
close during ischemia in the same way that endogenous
proteins do.
Conclusions
Our data show that Cx43 gene transfer to the healed scar
border resulted in overexpression of functional connexins
with phosphorylation and localization characteristics that
mirrored protein produced from endogenous gene expres-
sion. Increasing local connexin expression improved CV and
reduced VT inducibility, thus establishing a mechanistic
link between connexin expression and post-infarct VT
previously not possible in studies that could observe but not
intervene on Cx43 expression levels. An added benefit to the
CV strategy in comparison with manipulating repolariza-
tion is the absence of any theoretical possibility of triggered
arrhythmias in cells after gene transfer. Open questions
about the long-term durability of this effect, the safety in the
setting of recurrent ischemia, and the possibility of creating
new slow conduction zones require further study. With
resolution of these issues, connexin manipulation to im-
prove CV could become a novel therapy for arrhythmias
originating in the border of healed infarct scar.
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APPENDIX
For an expanded Methods section and supplemental figures and references,
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